600568.SH
ST中珠
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 2.16
−2.26%Year over year
Reported trailing growth
- Revenue
- +2.2%
- EBITDA
- —
- EBIT
- +80.1%
- EPS
- +80.3%
- Free cash flow
- —
- Operating cash flow
- -72.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.5%
- EBITDA
- +88.8%
- EBIT
- +80.2%
- Net income
- +81.6%
- EPS
- +80.6%
- Free cash flow
- +21.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026